You are here: Home ยป Archives for NASDAQ

Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution

  • Former President of Shire PLC’s (“Shire”) Specialty Pharmaceutical business, with more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, including senior leadership roles at Astra-Merck and AstraZeneca PLC
  • Proven leader in late-stage clinical development, global commercialization, and capital formation across central nervous system (“CNS”) programs
  • Appointed as Helus Pharma advances its pipeline toward key clinical milestones, including expected Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 later this year

This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

BOSTON and TORONTO, Feb. 10, 2026 (GLOBE NEWSWIRE) —  Helus PharmaTM (“Helus”) (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the appointment of Michael Cola as Chief Executive Officer, effective immediately.

Mr. Cola’s appointment comes at a pivotal moment as Helus advances its pipeline of next-generation mental health therapies toward key clinical and corporate value-inflection milestones, including the expected release of Phase 2 data for HLP004 this quarter and Phase 3 topline data for HLP003 in Q4 2026. In parallel, Helus continues to build a broad and defensible intellectual property estate spanning its multi-asset pipeline, with more than 350 patent applications filed globally and over 100 patents granted. The Company is advancing differentiated programs designed to address serious mental health disorders. With the transition from early clinical development to later-stage execution underway, the Company is increasingly focused on global regulatory engagement and long-term commercial planning. This evolution underscores the importance of experienced leadership across drug development, capital formation, and global scale-up.

“Michael brings a rare combination of deep neuroscience expertise, global commercialization experience, and proven capital markets leadership,” said co-founder and Executive Chairman Eric So. “As Helus advances its differentiated mental health pipeline, his track record of building first-in-class CNS franchises and scaling global organizations makes him uniquely suited to lead Helus as we work to translate our science into meaningful therapies for patients and long-term value for shareholders.”

With more than 30 years of experience across neuroscience, rare disease, and specialty pharmaceuticals, Mr. Cola brings deep expertise in guiding innovative CNS assets through development and into global markets, building high-performance organizations, and creating long-term shareholder value. His career spans senior leadership roles across R&D, commercialization, corporate strategy, and capital formation, positioning him to lead Helus through its next phase of growth.

“I am honored to join Helus at this pivotal and energizing moment,” said Mr. Cola. “With highly differentiated HLP003 clinical data already in hand and a robust pipeline of novel compounds in development, Helus is uniquely positioned to advance a new paradigm in the treatment of serious mental health disorders. I’m excited to work alongside the Board and the Helus team to build on this foundation and translate scientific progress into lasting patient and shareholder impact.”

As President of Shire’s Specialty Pharmaceutical business, Mr. Cola helped transform the company into a global CNS leader, launching and scaling breakthrough therapies, including building Vyvanse into a multi-billion-dollar franchise, and contributing to Shire’s growth from a $5 billion to a $20 billion market-capitalization, helping position the company for its subsequent $62 billion acquisition by Takeda, one of the largest pharmaceutical acquisitions in the industry. Earlier in his career, Mr. Cola was one of the founding hires at Merck selected to help create Astra-Merck, one of the most successful pharmaceutical spinouts, formed to commercialize Prilosec, a franchise that at one point generated more than $6 billion in annual revenue. He later held senior leadership roles at AstraZeneca PLC supporting the lifecycle expansion of Prilosec and the transition to Nexium.

More recently, Mr. Cola served as President and CEO of Avalo Therapeutics, Inc., where he led the transition to a rare disease and genomic medicine focus, licensed first-in-class clinical-stage assets, and raised significant funding. He has also served in senior board leadership roles, including as Chairman of Phathom Pharmaceuticals, Inc. and as a former board member of Sage Therapeutics, Inc., supporting organizations through clinical inflection points and commercial launches.

Mr. Cola holds a B.A. in Biology from Ursinus College, an M.S. in Biomedical Science and Engineering from Drexel University and studied Bioengineering at the University of Pennsylvania, where he also worked as a biomedical engineer at its affiliated hospital.

About Helus Pharma

Helus Pharma™, the commercial operating name of Cybin Inc., founded in 2019 (the “Company”), is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.

With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The Company operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus PharmaTM is a trademark of Cybin Corp.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s expectation to meaningfully advance the treatment of serious mental health disorders; the ability of the Company’s NSAs to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions; the release Phase 2 data for HLP004 in the first quarter of 2026 and Phase 3 topline data for HLP003 in the fourth quarter of 2026; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and six month periods ended September 30, 2025, and the Company’s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor Contact:
Josh Barer
astr partners
Managing Director
(908) 578-6478
[email protected]

George Tziras
Chief Business Officer
Helus Pharma
1-866-292-4601
[email protected] – or – [email protected]

Media Contact:
Johnny Tokarczyk
RXMD
Public Relations Director
[email protected]
(914) 772-7562


GLOBENEWSWIRE (Distribution ID 9651746)

AlloyX Group Announce USD100M Equity Financing to Accelerate Global Digital Asset Strategy

MANAMA, Bahrain, Feb. 10, 2026 (GLOBE NEWSWIRE) — AlloyX Group (AXG) officially announced the USD 100 million in equity financing during the Consensus Hong Kong event. The funds will be mainly allocated to the expansion of stablecoin and asset tokenization businesses, R&D in artificial intelligence and blockchain security technologies, as well as further investment in global market expansion.

As a world-leading comprehensive digital asset service platform, AXG has gained strong recognition from the capital market thanks to its sound and compliant operation system, clear global strategy, and sustainable growth potential. This round of financing not only underscores the market’s firm confidence in its long-term value and development prospects but also injects strong capital momentum into the company’s efforts to deepen the global stablecoin ecosystem, advance innovation in asset tokenization, and build secure and efficient digital financial infrastructure.

About AlloyX Group:
AlloyX Group (Nasdaq: AXG) is a global integrated financial services institution bridging traditional finance and digital assets ecosystem. The Group operates across stablecoin payments, tokenization service, digital brokerage, and on-chain financial infrastructure. By integrating traditional brokerage and banking systems with blockchain technology, AlloyX Group delivers secure, efficient, and auditable digital financial solutions for institutions. Backed by leading international investors, we are building the next generation digital financial infrastructure empowering the global transition toward a regulated digital economy.

Contact
Charlotte Qi
[email protected]


GLOBENEWSWIRE (Distribution ID 9651847)

WeRide and Uber to Deploy 1,200 Robotaxis in the Middle East

SAN FRANCISCO and GUANGZHOU, China, Feb. 06, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, and Uber Technologies, Inc. (NYSE: UBER) today announced a major expansion of their strategic partnership to deploy at least 1,200 Robotaxis across the Middle East. The deployment, which will span Abu Dhabi, Dubai, and Riyadh, is expected to be completed as soon as 2027.

WeRide and Uber's Robotaxi fleet in Abu Dhabi

All 1,200 Robotaxis will be available through the Uber app in the three markets, following existing fully driverless commercial Robotaxi operations in Abu Dhabi and passenger operations in Dubai and Riyadh. The fleet will be scaled up progressively, with Uber committed to adding more Robotaxis as key regulatory approvals and performance milestones are met, including the launch of fully driverless commercial operations covering the core areas of each city.

“Today’s announcement marks the largest Robotaxi commercial commitment in the MENA region. Supported by our existing fleet, bold regulators, and partners like Uber who share our ambition for safe and convenient mobility, this commitment accelerates our regional expansion and is a key part of our vision of tens of thousands of Robotaxis globally in the next five years,” said Dr. Tony Han, Founder and CEO of WeRide.

“This expansion with WeRide is an exciting moment for Uber and the Middle East. It is a testament to the strong performance of our existing deployments together, and we look forward to building on that momentum as we introduce more riders to autonomous mobility,” said Sarfraz Maredia, Global Head of Autonomous Mobility & Delivery at Uber.

With this expanded deployment, WeRide and Uber now operate Robotaxis in three of the 15 cities outlined under their previous agreement, with another 12 cities to come by 2030. The rollout follows WeRide’s asset–light operating model, with Uber or local third–party partners responsible for fleet operations. WeRide currently has more than 200 Robotaxis in the region.

In Abu Dhabi, the WeRide–Uber Robotaxi service is averaging dozens of daily trips per Robotaxi and is on track to achieve breakeven unit economics. Expanding the fleet to 1,200 Robotaxis will further strengthen WeRide’s position as a leading provider of commercial Robotaxi services in the Middle East, supported by a growing ecosystem of partners, and help to drive the region’s transition to fully autonomous urban mobility.

About WeRide
WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 40 cities across 11 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost–effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune's 2025 Change the World and 2025 Future 50 lists.

About Uber
Uber’s mission is to create opportunity through movement. We started in 2010 to solve a simple problem: how do you get access to a ride at the touch of a button? More than 72 billion trips later, we're building products to get people closer to where they want to be. By changing how people, food, and things move through cities, Uber is a platform that opens up the world to new possibilities.

Media Contacts
WeRide: [email protected]
Uber: [email protected]

Safe Harbor Statement
This press release contains statements that may constitute “forward–looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward–looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward–looking statements. Forward–looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward–looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f99cb47–e51a–457c–b653–bb18593a8256


GLOBENEWSWIRE (Distribution ID 9650174)

Cronos Group Launches Premium Lord Jones® Brand in Israel, Advancing Borderless Product Strategy

TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) (“Cronos” or the “Company”), a leading global cannabinoid company, today announced the launch of its Lord Jones® premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos’ borderless product strategy, expanding the Company’s globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world.

The first phase of the launch brings five premium indoor–grown flower strains to Israeli patients. Lord Jones®, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand’s expansion into Israel underscores Cronos’ commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences.

“Israel has always represented a key market in our borderless product strategy,” said Mike Gorenstein, Chairman, President and CEO of Cronos. “By introducing Lord Jones® to Israeli patients, we are applying our global brand expertise to meet local demand while preserving the craftsmanship, quality standards, and premium identity, which have come to define Lord Jones®. This launch reflects our disciplined approach to international expansion and reinforces our commitment to building globally relevant cannabis brands anchored in quality and innovation.”

Lord Jones® cannabis flower is produced through a meticulous approach that begins with carefully selected genetics and continues through small batch indoor cultivation. Following harvest, the Lord Jones® cannabis products undergo a cold‑cure process designed to preserve terpene richness, aroma, trichome density, and overall flower structure. Each batch is hand‑trimmed, produced in limited quantities, and tested extensively to meet rigorous standards. To maintain freshness and protect terpene profiles over time, the finished product is hand packaged in glass jars, which helps shield the flower from light exposure and preserve its quality.

“The launch of the Lord Jones® brand in Israel marks an important milestone for us, bringing a premium standard to the Israeli medical market, which is grounded in expertise and intention,” said Adam Wagner, General Manager of Cronos Israel. “Every stage of our work is guided by rigorous oversight and meticulous processes, from genetics and cultivation through meticulous processing and hand packaging. This end–to–end approach gives patients and pharmacists confidence in the standards behind the brand, delivering a premium defined by transparency and an unwavering commitment to quality.”

In addition to the core flower offering, Cronos plans to expand the Lord Jones® brand in Israel with future special edition and limited‑run products. Lord Jones® products are now available in pharmacies across Israel.

About Cronos Group Inc. 
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com. 
 
Forward–looking Statements  
This press release may contain information that may constitute “forward–looking information” or “forward–looking statements” within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, “Forward–looking Statements”). All information contained herein that is not clearly historical in nature may constitute Forward–looking Statements. In some cases, Forward–looking Statements can be identified by the use of forward–looking terminology such as “may”, “will”, “expect”, “plan”, “anticipate”, “intend”, “potential”, “estimate”, “believe” or the negative of these terms, or other similar expressions intended to identify Forward–looking Statements. Some of the Forward–looking Statements contained in this press release include statements about the Company’s borderless product strategy, international growth and expansion, expectations regarding market trends, consumer preferences, pricing dynamics; demand for premium cannabis products; the anticipated benefits of the launch of the Lord Jones® brand in Israel; future Lord Jones® product offerings in Israel; and the Company’s intention to build an international iconic brand portfolio and develop disruptive intellectual property by advancing cannabis research, technology and product development. Forward–looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward–looking Statements and the Forward–looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10–K for the year ended December 31, 2024 and the Company’s Quarterly Reports on Form 10–Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward–looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward–looking Statement. Readers are cautioned not to put undue reliance on any Forward–looking Statement. 
 
For further information, please contact:  
 
Media Relations Contact:
Emily Whalen  
Communications  
Tel: (416) 504–0004  
[email protected]   
 
Investor Relations Contact:
Harrison Aaron  
Investor Relations  
Tel: (416) 504–0004  
[email protected]  


GLOBENEWSWIRE (Distribution ID 9647193)

AirJoule Technologies تُبرم شراكة إستراتيجية مع شركة TenX Investment للتوزيع الحصري في الشرق الأوسط

RONAN, ،مونتانا،, Feb. 02, 2026 (GLOBE NEWSWIRE) —

أعلنت اليوم شركة AirJoule Technologies Corporation (NASDAQ: AIRJ) (يُشار إليها فيما يلي باسم “AirJoule Technologies” أو “AIRJ”)، وهي منصة تكنولوجية رائدة تُسخّر إمكانات استخراج المياه من الهواء، عن إبرام اتفاقية مع شركة TenX Investment in Energy Enterprises & Management Co (يُشار إليها فيما يلي “TenX Investment”)، وهي شركة استثمارية في مجالي التكنولوجيا والبنية التحتية مقرها دولة الإمارات العربية المتحدة ومملوكة بالكامل لمواطنين إماراتيين، لتصبح TenX Investment الموزِّع الحصري لمنتجات AirJoule التابعة لشركة AIRJ في منطقة الشرق الأوسط.

تمكين AirJoule من معالجة أمن المياه في الشرق الأوسط

يمثل هذا الإنجاز تقدمًا مهمًا يُبنى على مذكرة التفاهم التي أُعلن عنها في آب/ أغسطس 2024، ويضع AIRJ في موقع يمكّنها من اغتنام فرص سوقية كبيرة في منطقة تشهد نموًا متسارعًا رغم معاناتها من شحّ المياه. وبموجب الاتفاقية، ستحصل شركة TenX Investment على حقوق حصرية لتسويق نُظم توليد المياه المُوزَّعة ونُظم إزالة الرطوبة الصناعية من AirJoule وبيعها ودعمها في كلٍ من الإمارات العربية المتحدة، وعُمان، وقطر، والمملكة العربية السعودية، والبحرين، والكويت. ومن المقرر أن تُدرج الشروط التجارية في اتفاقية نهائية قبل بدء عمليات النشر التجاري الأولية، والمُخطط لها في أواخر عام 2026.

يتيح التعاون مع TenX Investment لشركة AIRJ وصولًا فوريًا إلى السوق وخبرة محلية وعلاقات راسخة عبر القطاعات الحكومية والتجارية والصناعية، في منطقة تشهد نموًا هائلًا في تطوير مراكز البيانات والتصنيع المتقدم والاستثمارات في البنية التحتية—وهي جميعها قطاعات تتطلب مستويات حرجة من أمن المياه. وتسعى الحكومات والشركات بشكل متزايد إلى تبني تقنيات قادرة على تعزيز أمن المياه مع خفض كثافة استهلاك الطاقة.

تعتمد تقنية منصة AirJoule على الاستفادة من الحرارة المهدرة، وتستخدم الهياكل الفلزية العضوية وغرف التفريغ لفصل المياه عن الهواء بكفاءة عالية، ما يجعلها الوحيدة الملائمة لتعزيز استدامة المياه في المنطقة. وتنتج نُظم AirJoule مياهًا مقطرة نقية على نطاقٍ صناعي لدعم نُظم التبريد وغيرها من العمليات الصناعية، كما تضمن كفاءة إزالة رطوبة رائدة في السوق، ما يحقق وفورات كبيرة في الطاقة للعملاء.

شراكة إستراتيجية تستفيد من الخبرة الإقليمية لشركة TenX Investment

صرّح Matt Jore، الرئيس التنفيذي لشركة AirJoule Technologies: “يمثل توسيع علاقتنا التجارية مع TenX Investment علامةً فارقةً في إستراتيجية التوسع الدولي لشركة AirJoule Technologies، ويضعنا في موقع يمكّننا من اقتناص فرص بارزة في أحد أكثر الأسواق جاذبية في العالم لتوليد المياه الموزعة”.

ومن جانبه، أعّرب Ramdas Rao، رئيس الشؤون الدولية في AirJoule Technologies، قائلًا: “يواجه الشرق الأوسط ومنطقة الجنوب العالمي الأوسع نطاقًا تحديات استثنائية في مجال أمن المياه، بالتزامن مع نمو سريع في مراكز البيانات، والتصنيع المتقدم، وتطوير البنية التحتية. وتقدّم TenX Investment الإمكانيات التي نحتاجها لتسريع اختراق السوق، شاملةً العلاقات الإقليمية العميقة، وخبرة تسويقية مثبتة، وفهمًا دقيقًا لمتطلبات الأعمال والبيئات التنظيمية.”

وقال Abdulnasser Al–Sharafi، الشريك في TenX Investment: “نشعر بالحماس لإضفاء الطابع الرسمي على شراكتنا مع AirJoule Technologies والتقدّم نحو أن نصبح الموزّع الحصري لهم في الشرق الأوسط”. وأضاف: “إن تقنية منصة AirJoule المبتكرة تعالج أحد أكثر التحديات التي تواجه منطقتنا إلحاحًا، ألا وهو—أمن المياه—وفي الوقت ذاته تدعم إستراتيجيات التنويع الاقتصادي الوطنية والتزامات الاستدامة. وقد أثبتت AirJoule أداءً لافتًا في مناخ دبي القاسي، وتلقّينا اهتمامًا كبيرًا من عملاء في القطاعين الحكومي والخاص الباحثين عن حلول مستدامة للمياه. ونعتقد أن هذه الاتفاقية ستُرسّخ أساسًا متينًا لتوسيع نطاق استخدام النظام في جميع أنحاء المنطقة خلال السنوات المقبلة.”

نظام العرض التجريبي في دبي يمثّل علامةً فارقةً في مسيرة التسويق التجاري

خلال الفترة من شباط/ فبراير 2025 إلى كانون الأول/ ديسمبر 2025، قامت AIRJ وTenX Investment بتشغيل نظام عرض تجريبي من AirJoule في Dubai Future Lab، حيث واصل النظام إثبات أداءه وكفاءته في ظل الظروف المناخية القاسية للمنطقة. وعمل النظام عبر تقلبات كبيرة في درجات الحرارة والرطوبة، مولّدًا مياهًا مُقطّرة عالية النقاء، ومُبرهنًا على موثوقية تشغيلية عالية. وأسهم نظام العرض التجريبي في توليد بيانات داخلية لأغراض التحسين المستقبلي، وتيسير المناقشات مع العملاء الخارجيين، وتسريع وتيرة الاهتمام التجاري.

نبذة عن شركة AirJoule Technologies Corporation

تُعد شركة AirJoule Technologies Corporation (NASDAQ: AIRJ) منصة تكنولوجية رائدة تُسخّر إمكانات استخراج المياه من الهواء. ومن خلال مشروعها المشترك مع GE Vernova، وبالشراكة مع Carrier Global Corporation، تتمثل رسالة الشركة في تحرير العالم من قيوده المتعلقة بالمياه والطاقة عبر تقديم تقنيات امتزاز رائدة تُحدث نقلة نوعية. لمزيد من المعلومات، يُرجى زيارة https://airjouletech.com.

يُرجى متابعة AirJoule Technologies على LinkedIn: https://www.linkedin.com/company/airjoule–tech/

نبذة عن شركة TenX Investment

تتخصص TenX Investment in Energy Enterprises & Management Co. LLC في الاستثمار وجلب أفضل حلول الطاقة العالمية إلى دولة الإمارات العربية المتحدة ومنطقة الشرق الأوسط وشمال إفريقيا الأوسع نطاقًا. وبصفتها شركة استثمارية صغيرة ومتوسطة مملوكة بالكامل لمواطنين إماراتيين في دولة الإمارات العربية المتحدة، تستفيد الشركة من شبكة علاقاتها الواسعة وشراكاتها الإستراتيجية لإتاحة وصول غير مسبوق إلى تقنيات وخدمات الطاقة المبتكرة، بما يضمن بقاء عملائها في صدارة قطاع يشهد تطورًا متسارعًا. وإضافةً إلى ذلك، تستثمر الشركة في تقنيات متقدمة لدعم التطورات المستدامة في مجال الطاقة، ما يعزز التزامها بدفع الكفاءة والاستدامة في قطاع الطاقة. لمزيد من المعلومات، يُرجى زيارة www.10xinvestment.ae.

حماية العلامات التجارية

يُعدّ اسم شركة AirJoule Technologies وشعاراتها واسم موقعها الإلكتروني وعنوانه علامات تجارية أو علامات خدمية. ولأغراض التسهيل فقط، وفي بعض الحالات، تُدرج العلامات التجارية والأسماء التجارية والعلامات الخدمية المذكورة في هذا البيان الصحفي دون الرموز ® و™ وSM، إلا أن شركة AirJoule Technologies، وفقًا لأحكام القانون المعمول به، ستشدّد على حقوقها في هذه العلامات التجارية والأسماء التجارية والعلامات الخدمية.

جهات الاتصال
علاقات المستثمرين والإعلام:
Tom Divine – نائب الرئيس، علاقات المستثمرين والشؤون المالية
[email protected]

تتوفر صورة مرافقة لهذا الإعلان على الرابط التالي 

https://www.globenewswire.com/NewsRoom/AttachmentNg/0e882ebd–8892–4dae–aaa1–be484b0b3c8b

 


GLOBENEWSWIRE (Distribution ID 9646389)

AirJoule Technologies to Form Strategic Partnership with TenX Investment for Exclusive Middle East Distribution

RONAN, Mont, Feb. 02, 2026 (GLOBE NEWSWIRE) — AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or “AIRJ”), a leading technology platform that unleashes the power of water from air, today announced an agreement with TenX Investment in Energy Enterprises & Management Co (“TenX Investment”), a wholly Emirati–owned UAE–based technology and infrastructure investment firm, to become AIRJ’s exclusive distributor of AirJoule products in the Middle East region.

Positioning AirJoule to Address Water Security in the Middle East

This milestone represents significant advancement building on the Memorandum of Understanding announced in August 2024 and positions AIRJ to capture substantial market opportunities in a rapidly growing yet water–stressed region. Under the agreement, TenX Investment will have exclusive rights to market, sell, and support AirJoule distributed water generation and industrial dehumidification systems in the countries of UAE, Oman, Qatar, Saudi Arabia, Bahrain, and Kuwait. Commercial terms are to be reflected in a definitive agreement ahead of initial commercial deployments, which are planned for late 2026.

The collaboration with TenX Investment provides AIRJ with immediate market access, local expertise, and established relationships across government, commercial, and industrial sectors in a region experiencing explosive growth in data center development, advanced manufacturing, and infrastructure investment—all sectors with critical water security requirements. Governments and enterprises are increasingly seeking technologies that can strengthen water security while reducing energy intensity.

The AirJoule platform technology, which leverages waste heat and utilizes metal–organic frameworks and vacuum chambers to efficiently separate water from air, is uniquely suited to improve water sustainability in the region. AirJoule systems produce pure distilled water at industrial scale to support cooling systems and other industrial processes, and AirJoule’s market–leading dehumidification efficiency delivers significant energy savings for customers.

Strategic Partnership Leveraging TenX Investment's Regional Expertise

“Expanding our commercial relationship with TenX Investment represents a pivotal milestone in AirJoule Technologies' international expansion strategy and positions us to capture significant opportunities in one of the world's most compelling markets for distributed water generation,” said Matt Jore, Chief Executive Officer of AirJoule Technologies.

Ramdas Rao, President, International of AirJoule Technologies, said, “The Middle East and broader Global South face extraordinary water security challenges while simultaneously experiencing rapid growth in data centers, advanced manufacturing, and infrastructure development. TenX Investment brings the capabilities we need to accelerate market penetration, such as deep regional relationships, proven commercialization expertise, and an intimate understanding of business requirements and regulatory environments.”

“We are excited to formalize our partnership with AirJoule Technologies and advance toward becoming their exclusive Middle East distributor,” said Abdulnasser Al–Sharafi, Partner at TenX Investment. “AirJoule's innovative platform technology addresses one of the most critical challenges facing our region—water security—while simultaneously supporting national economic diversification strategies and sustainability commitments. AirJoule has demonstrated compelling performance in Dubai's demanding climate, and we've received substantial interest from government and private sector customers seeking sustainable water solutions. We believe this agreement will establish a strong foundation for scaling deployments across the region in the coming years.”

Dubai Demonstration System is an Important Milestone in Commercialization

From February 2025 to December 2025, AIRJ and TenX Investment operated an AirJoule demonstration system at the Dubai Future Lab that consistently validated performance in the region's extreme climate conditions. The system operated through wide temperature and humidity swings, generating high purity distilled water and demonstrating operational reliability. This demonstration was successful in generating internal data for future optimization, facilitating external customer discussions and accelerating commercial interest.

About AirJoule Technologies Corporation

AirJoule Technologies Corporation (NASDAQ: AIRJ) is a leading technology platform that unleashes the power of water from air. Through its joint venture with GE Vernova and in partnership with Carrier Global Corporation, the company’s purpose is freeing the world of its water and energy constraints by delivering groundbreaking sorption technologies. For more information, visit https://airjouletech.com.

Follow AirJoule Technologies on LinkedIn: https://www.linkedin.com/company/airjoule–tech/

About TenX Investment

TenX Investment in Energy Enterprises & Management Co. LLC specializes in investing and bringing the best international energy solutions to the UAE and the broader MENA region. As a wholly Emirati–owned SME investment company in the UAE, we leverage our extensive connections and strategic partnerships to provide unparalleled access to innovative energy technologies and services, ensuring our clients stay ahead in a rapidly evolving industry. Additionally, we invest in cutting–edge technologies to further support sustainable energy advancements, reinforcing our commitment to driving efficiency and sustainability in the energy sector. For more information, visit www.10xinvestment.ae.

Trademark Protection

AirJoule Technologies’ name, logos and website name and address are trademarks or service marks. Solely for convenience, in some cases, the trademarks, trade names and service marks referred to in this press release are listed without the applicable®,™ and SM symbols, but AirJoule Technologies will assert, to the fullest extent under applicable law, its rights to these trademarks, trade names and service marks.

Contacts
Investor Relations & Media:
Tom Divine – Vice President, Investor Relations and Finance
[email protected]

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0e882ebd–8892–4dae–aaa1–be484b0b3c8b


GLOBENEWSWIRE (Distribution ID 9646389)

Zoom to Release Financial Results for the Fourth Quarter and Full Fiscal Year 2026

SAN JOSE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the fourth quarter and full fiscal year 2026 on Wednesday, February 25, 2026, after the market closes.

A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom (NASDAQ:ZM) provides the AI–first, open work platform built for human connection and purposefully designed to move conversations to completion. From entrepreneurs to global enterprises, customers choose Zoom to seamlessly collaborate, communicate, and drive outcomes across meetings, chat, phone, contact center, events, and more — all with the built–in assistance of Zoom AI Companion. Founded in 2011, Zoom is headquartered in San Jose, CA. For more information, visit zoom.com.

Public Relations
Karen Modlin
Head of Corporate Communications, Zoom
[email protected]

Investor Relations
Charles Eveslage
Head of Investor Relations, Zoom
[email protected]


GLOBENEWSWIRE (Distribution ID 9645546)

Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call

DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question–and–answer session.

To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.

A replay of the live conference call will be available shortly after the conclusion of the event and accessible on the events and presentations section of the Fortrea Investor Relations website.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I–IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

Fortrea Contacts

Tracy Krumme (Investors) – 984–385–6707, [email protected]

Sue Zaranek (Media) – 919–943–5422, [email protected]

Kate Dillon (Media) – 646–818–9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9645303)

WeRide GENESIS Unites Physical and Generative AI to Redefine Autonomous Driving Simulation

GUANGZHOU, China, Jan. 27, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, today announced the launch of WeRide GENESIS1, its proprietary general–purpose simulation model. WeRide GENESIS bridges physical AI and generative AI, connecting the real and simulated worlds to accelerate the development, training, and validation of autonomous vehicles (AVs) at scale.

Leveraging generative AI, WeRide GENESIS can rapidly generate highly realistic virtual worlds, building simulated cities within minutes and accurately reproducing rare, extreme real–world driving scenarios that are difficult to capture on actual roads. This enables AVs to undergo large–scale training and validation in simulation. Insights generated are continuously fed back into real–world operations – significantly enhancing AV performance in complex scenarios, speeding up iteration cycles, and reducing time and cost compared to traditional road testing.

WeRide GENESIS was developed to address the challenges of commercializing autonomous driving on a global scale. Cities differ greatly in road networks, traffic behaviors, infrastructure, weather conditions, and regulatory environments, placing greater demands on the generalization capabilities of autonomous driving technology. However, real–world testing is costly, slow, and limited in scenario coverage, making large–scale validation across multiple cities and conditions extremely difficult. A high–fidelity simulation platform capable of fully replicating real–world environments has therefore become indispensable.

Such simulation platforms allow AVs to “drive” in virtual cities, exposing AI drivers to diverse road, weather, and traffic scenarios – including rare and high–risk events. This overcomes the cost and coverage constraints of real–world testing, improves training efficiency, and ensures AVs are safer and more reliable on real roads.

As one of the industry's most advanced autonomous driving simulation platforms, WeRide GENESIS integrates four core AI modules – AI Scenarios, AI Agents, AI Metrics, and AI Diagnosis – to handle any driving scenario, create virtual worlds in minutes, and replicate real–world conditions with centimeter–level fidelity. This provides powerful support for the training, validation, and iteration of autonomous driving algorithms.

1.  A “Lego” world with unlimited combinations

Leveraging generative AI, WeRide GENESIS builds highly realistic cities in minutes, accurately reproducing road infrastructure, weather conditions, environmental details, and diverse traffic behaviors from around the world.

Within this “Lego city”, the AI Scenarios module simulates a wide–range of key scenarios that AVs could face on real roads. This includes sudden vehicle cut–ins, unprotected left turns, emergency evasive maneuvers, pedestrian or rider intrusions, and extreme events such as fires, earthquakes, road blockages, and bad weather. The module draws on billions of kilometers of real–world driving data, and over eight years of long–tail edge cases from WeRide's public road operations, ensuring AV systems are equipped to handle complex edge scenarios.

2.  High–fidelity interaction with agile responses

High–fidelity modeling of road users is widely regarded as one of the most challenging problems for autonomous driving simulation. The key difficulty lies in moving beyond representing an “average” road user to accurately capture unpredictable behaviors in the real world – for example, a human driver abruptly cutting into the lane of an AV.

To address this, WeRide GENESIS introduced the AI Agents module, which builds intelligent behavior models for human drivers, pedestrians, riders, and other road users. These models realistically simulate the full spectrum of traffic behaviors, from routine driving to high–risk actions.

By combining intelligent scenario sampling with behavior modeling, WeRide GENESIS can simulate a wide variety of road types, traffic conditions, and the distribution of dynamic and static participants. This allows tech teams to evaluate AV decision–making safety and system robustness under different algorithm configurations, predict performance across multiple Operational Design Domains (ODDs), and continuously improve iteration efficiency and quality.

3.  Closed–loop optimization with continuous feedback

Safety and passenger comfort remains a core priority of autonomous driving, and WeRide GENESIS enhances this through the AI Metrics and AI Diagnosis modules, forming a systematic closed–loop framework for evaluation and optimization.

The AI Metrics module provides a quantitative evaluation system covering safety, compliance, comfort, and travel efficiency. It translates driving behaviors into measurable performance metrics, enabling automated assessment of algorithm improvements. For example, passenger discomfort caused by sudden braking is captured as a specific Comfort Score and fed back to algorithm teams in real–time for targeted optimization and revalidation.

The AI Diagnosis module automates root–cause analysis and provides recommendations for improvement. It can detect sub–optimal driving behaviours, analyze their underlying causes, and provide actionable solutions. For example, when an AV encounters perception delays or prediction errors in complex interactive scenarios, the system can quickly diagnose, fix, and revalidate performance, ensuring the vehicle constantly behaves as expected.

4.  One platform for global use

WeRide GENESIS is a highly versatile simulation platform that supports diverse urban road conditions, sensor perspectives and vehicle configurations. It can accommodate a range of AVs, from Level 2++ advanced driver–assistance systems to autonomous Level 4 Robotaxis. This allows WeRide's AI drivers worldwide to be trained and tested on a single platform without the need for separate simulations for different cities or vehicle types, optimizing R&D resources and accelerating AV deployment.

This technological strength has helped WeRide become the only technology company whose products hold autonomous driving permits in eight countries, with AVs present in over 40 cities across 11 countries, maintaining a leading position in global commercial deployments.

Through its four core AI modules, WeRide GENESIS has built a complete closed–loop iteration system that automatically generates high–fidelity scenarios, identifies performance bottlenecks, highlights weak points, and suggests improvements. This condenses millions of kilometers of road testing into a few days of virtual simulation, creating a true “acceleration flywheel” for WeRide's technology evolution.

“WeRide GENESIS builds us a digital universe that can be generated, scaled, and evolved on demand. With it, our AI drivers can familiarize themselves with the driving environment of any city worldwide within minutes, laying a solid technical foundation for the global commercialization of autonomous driving. This represents a true leap forward in industry capability,” said Dr. Yan Li, Co–Founder and CTO of WeRide.

The launch of WeRide GENESIS showcases WeRide’s global leadership in autonomous driving simulation, AI agent modeling, and closed–loop iteration, marking a transformative breakthrough in the application of physical AI.

About WeRide
WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 40 cities across 11 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost–effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune's 2025 Change the World and 2025 Future 50 lists.

Media Contact
[email protected]

Safe Harbor Statement
This press release contains statements that may constitute “forward–looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward–looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward–looking statements. Forward–looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward–looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b79232f4–8cf5–411e–a780–1ed51c9c42b5

____________________
1 Generative Engineered Neural Environment for Simulated Intelligence in Self–driving


GLOBENEWSWIRE (Distribution ID 9643495)

Zoom Opens Nominations for First U.S. Solopreneur 50 List, Recognizing AI-First Solo Business Leaders

SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Today, Zoom opens nominations for its Zoom Solopreneur 50 List (ZSP50), a first–of–its–kind recognition and grant program celebrating the individuals who are redefining entrepreneurship by building and growing businesses on their own.

Nominations are open until 5 p.m. ET on February 13, 2026. Individuals can nominate themselves or others by completing a short form at zoom.com/solo50.

The ZSP50 will honor 50 trailblazing “businesses of one” across the U.S. — independent creators, consultants, educators, inventors, and innovators using technology, ingenuity, and purpose to make an outsized impact. For business owners working alone, this is the opportunity to be part of a select group of doers with similar drive and grit.

“AI is expanding what a single person can accomplish,” said Kimberly Storin, Chief Marketing Officer at Zoom. “Solopreneurs are using AI to remove friction, move faster, reach further, and operate with a level of sophistication that used to be out of reach. The Solopreneur 50 recognizes the builders proving that scale today is driven by capability, not company size. Zoom is focused on enabling that future.”

Scaling Solos with AI

There are over 30MM small businesses in the U.S., 82% of which operate without employees (U.S. Chamber of Commerce). For an increasing number of solopreneurs, AI has become a core operating capability, enhancing decision–making, execution, and customer engagement.

Zoom, in partnership with Upwork, recently surveyed more than 1,000 small businesses (SMB), including solopreneurs, 64% of whom said they couldn’t be in business without AI. What’s more, 91% of small businesses saw a return on their AI investments within one year, and SMBs and solopreneurs report that AI has helped them reduce business costs (82%), increase customer acquisition (91%), and increase customer retention (87%).

Many solopreneurs can quickly adopt and iterate with AI tools, unencumbered by legacy systems or lengthy approval processes, allowing them to test, learn, and apply new capabilities in real time.

“Some of the most effective uses of AI aren’t coming from big companies – they’re solopreneurs,” said Lisa Scheiring, Global Small Business Advisor (informally known as the “Chief Solo Officer”) at Zoom. “They’re not waiting for polished playbooks or permission; they’re using AI to solve real problems in real time, from gaining continuous visibility into operations, to accessing expertise on demand, to turning a single hour of work into an entire marketing campaign. That speed and agility are real advantages, and it’s reshaping what’s possible for armies of one.”

The ZSP50 is part of Zoom’s broader initiative to provide independent business builders with research, recognition, and real–world tools to scale their success.

The ZSP50 Program

The ZSP50 recognizes a growing community of individuals who operate and scale their ventures independently, with no full–time employees, across multiple sectors including but not limited to technology and design, wellness, media, and social impact.

Eligible nominees must:

  • Operate a U.S.–based business with no full–time employees
  • Have been in operation for at least 12 months
  • Demonstrate innovation, independence, and measurable impact

A jury of experts drawn from Zoom’s network will evaluate solopreneur nominees across five dimensions that reflect what it takes to build a durable solo business today:

  • Originality of idea or execution
  • Demonstrated financial performance
  • Measurable business impact
  • Authentic connection to culture and community
  • Influence in shaping conversations, markets, or communities.

Honorees will be announced in Q2 2026, and gain exposure through Zoom’s platforms and media ecosystem, access to a community of peers and mentors, and eligibility for financial grants awarded to the top–five honorees to accelerate their growth and impact.

For more information, visit zoom.com/solo50. Contact Zoom at [email protected] with additional questions or inquiries.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion that empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California.

Get more information at zoom.com.

Media Contact
[email protected]
[email protected]


GLOBENEWSWIRE (Distribution ID 9621773)